We are investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cash.
If you remain an Exact Sciences shareholder and have concerns about the fairness of the sale price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On November 20, 2025, Exact Sciences announced that it had agreed to be sold to Abbott for $105.00 per share in cash.
“We are investigating whether the Exact Sciences Board of Directors acted in the best interests of Exact Sciences shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Exact Sciences shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”